• Wondering if Cardinal Health at around US$211 a share still offers value, or if most of the opportunity is already reflected in the price.
• The stock has returned 2.0% over the last week, seen a 7.8% decline over the last 30 days, yet is up 2.7% year to date and 55.8% over the past year, with very large gains over 3 and 5 years.
• Recent headlines have focused on Cardinal Health's broader role as a major healthcare distributor and solutions provider, which keeps attention on how its scale and reach affect investor expectations. News around the sector's pricing power, regulatory attention and supply chain reliability continues to shape how the market views risk and reward for the shares.
• On Simply Wall St's 6 point valuation checklist, Cardinal Health scores a 3 out of 6. Next comes a closer look at what different valuation methods say about that price tag and why a more complete way of thinking about value at the end of this article could matter even more.

Approach 1: Cardinal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a present value. It focuses on the cash the business may generate for shareholders rather than short term market moves.

For Cardinal Health, the model uses a 2 stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $5.52b. Analyst based projections run through 2030, with Simply Wall St extending the path further using its own estimates. For example, projected free cash flow for 2030 is $4.49b, with intermediary years between 2026 and 2035 ranging from about $2.84b to $5.84b before discounting.

When all these projected cash flows are discounted back and aggregated, the implied intrinsic value from this DCF is about $495.89 per share. Compared with the current share price of around $211, this model suggests Cardinal Health trades at roughly a 57.4% discount to that estimate, and the shares appear undervalued on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cardinal Health is undervalued by 57.4%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Approach 2: Cardinal Health Price vs Earnings

For profitable companies, the P/E ratio is a useful check on value because it links what you pay for each share directly to the earnings that support it. Higher growth expectations and lower perceived risk usually justify a higher P/E, while slower growth or higher uncertainty tend to align with a lower, more conservative multiple.

Cardinal Health currently trades on a P/E of 29.92x. That sits above the Healthcare industry average of 22.84x and also above the peer group average of 23.66x, which might suggest a richer valuation at first glance. Simply Wall St adds another layer with its proprietary Fair Ratio, which is 33.48x for Cardinal Health.

The Fair Ratio indicates the P/E that could be reasonable given factors such as earnings growth, industry, profit margins, market cap and company specific risks. Because it blends these drivers into a single figure, it can be more tailored than relying only on peer or industry comparisons.

Comparing the current P/E of 29.92x with the Fair Ratio of 33.48x, Cardinal Health trades below that Fair Ratio, which points to the shares looking undervalued on this earnings based view.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Cardinal Health Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives let you attach a clear story about Cardinal Health to the numbers by linking your view of its business, such as specialty expansion, home healthcare exposure, regulatory and reimbursement risks or automation benefits, to a forecast for revenue, earnings and margins, and then to a fair value that you can compare with the current share price.

On Simply Wall St's Community page, Narratives are an accessible tool used by millions of investors, helping you see how different assumptions lead to different fair values, and giving you a quick way to sense check whether you think the current price looks high or low relative to your own expectations.

Narratives are kept current as new information arrives, such as earnings reports, tariff related commentary, guidance updates, buyback activity or changes in analyst targets. This means your story and its fair value estimate for Cardinal Health are not static.

For example, one investor might focus on growth in pharmaceuticals and specialty distribution, operational efficiency and higher margin specialty businesses and arrive at a fair value close to US$275.0. Another might focus on regulatory pressure, customer concentration and tariff risks and anchor closer to US$200.0. Seeing both side by side can help you decide how your own view compares.

Do you think there's more to the story for Cardinal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.